|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Revenues | ||
| Cost of revenues | ||
| Gross profit | ||
| Operating expenses: | ||
| Selling and marketing expenses | ||
| General and administrative expenses | ||
| Research and development expenses | ||
| Total operating expenses | ||
| Income/(loss) from operations | ||
| Interest expense, net | ||
| Interest income | ||
| Subsidy income | ||
| Other expenses, net | ||
| Income/(loss) before income tax | ||
| Income tax provision | ||
| Net income/(loss) | ||
| Less: Net Loss/(income) attributable to non-controlling interests | ||
| Net income attributable to Baird Medical Investment Holdings Limited's shareholders | ||
| Net income/(loss) attributable to Baird Medical Investment Holdings Limited's shareholders | ||
| Other comprehensive loss | ||
| Foreign currency translation adjustment | ||
| Total comprehensive income | ||
| Total comprehensive income/(loss) | ||
| Less: Non-controlling interests | ||
| Comprehensive income/(loss) attributable to Baird Medical Investment Holdings Limited's shareholders | ||
| Net income/(loss) per share, basic (in dollars per share) | ||
| Net income/(loss) per share, diluted (in dollars per share) | ||
| Weighted average number of shares - basic (in shares) | ||
| Weighted average number of shares - diluted (in shares) | ||
| Stock-based compensation expenses | ||
| General and administrative expenses | ||
| Selling and marketing expenses | ||
| Total stock-based compensation expenses |
Loading...
